{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T23:37:05Z","timestamp":1777246625864,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10140021910501"],"award-info":[{"award-number":["10140021910501"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dose reduction of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukaemia (CML) can reduce side effects and improve quality of life while maintaining treatment effectiveness and reducing costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study evaluates the views of both patients with CML and healthcare providers involved in CML care on dose reduction of TKIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A qualitative study with semi-structured interviews via phone or video call was conducted with Dutch adult patients with CML and their healthcare providers. The COM-B model served as a theoretical framework to guide data collection and analysis to understand participants\u2019 capability, opportunity, and motivation for dose reduction. An inductive coding approach was utilized to derive themes from the data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen patients and twelve healthcare providers (haematologists, nurse specialists, and pharmacists) participated, who in general were supportive of dose reduction. Two main themes were identified: (1) willingness and acceptance of dose reduction, which was shaped by participants\u2019 beliefs about the use of TKIs, the impact of TKIs on patients\u2019 quality of life, and associated hopes, fears and concerns; and (2) needs and preferences regarding dose reduction such as timing, eligibility, practical aspects, and shared-decision making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients and healthcare providers have positive views on TKI dose reduction to improve the burden of CML treatment. Acceptance is shaped by their beliefs and concerns, while successful implementation depends on addressing practical needs and shared-decision making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag114","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:49:11Z","timestamp":1774702151000},"source":"Crossref","is-referenced-by-count":0,"title":["Patients\u2019 and healthcare providers\u2019 views regarding dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: a qualitative study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0741-8722","authenticated-orcid":false,"given":"Dina N","family":"Lokhorst","sequence":"first","affiliation":[{"name":"Department of Hematology, Radboud University Medical Center , Nijmegen, 6525 GA,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8560-9514","authenticated-orcid":false,"given":"Bart J F","family":"van den Bemt","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sint Maartenskliniek , Nijmegen, 6574 NA,","place":["The Netherlands"]},{"name":"Department of Pharmacy, pharmacology and toxicology, Radboud University Medical Center , Nijmegen, 6525 GA,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4799-4981","authenticated-orcid":false,"given":"Yolba","family":"Smit","sequence":"additional","affiliation":[{"name":"Department of Hematology, Radboud University Medical Center , Nijmegen, 6525 GA,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosella P M G","family":"Hermens","sequence":"additional","affiliation":[{"name":"IQ Health, Radboud University Medical Center , Nijmegen, 6525 GA,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1801-2072","authenticated-orcid":false,"given":"Nicole M A","family":"Blijlevens","sequence":"additional","affiliation":[{"name":"Department of Hematology, Radboud University Medical Center , Nijmegen, 6525 GA,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6018-4409","authenticated-orcid":false,"given":"Charlotte L","family":"Bekker","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, pharmacology and toxicology, Radboud University Medical Center , Nijmegen, 6525 GA,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026042618471895900_oyag114-B1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"JCO"},{"key":"2026042618471895900_oyag114-B2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/10428194.2020.1855340","article-title":"Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees","volume":"62","author":"Chow","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2026042618471895900_oyag114-B3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12885-023-10697-6","article-title":"Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study): study protocol for a prospective, multicentre, single-arm trial","volume":"23","author":"Djodikromo","year":"2023","journal-title":"BMC Cancer"},{"key":"2026042618471895900_oyag114-B4","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol"},{"key":"2026042618471895900_oyag114-B5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.17286","article-title":"TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia","volume":"193","author":"Claudiani","year":"2021","journal-title":"Br J Haematol"},{"key":"2026042618471895900_oyag114-B6","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3390\/pharmaceutics15051363","article-title":"A real-world evidence-based study of long-term tyrosine kinase inhibitors dose reduction or discontinuation in patients with chronic myeloid leukaemia","volume":"15","author":"Mart\u00edn Rold\u00e1n","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026042618471895900_oyag114-B7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.clml.2024.01.008","article-title":"The italian multicentric randomized OPTkIMA trial on fixed vs progressive intermittent TKI therapy in CML elderly patients: 3-Years of molecular response and quality of life monitoring after completing the treatment plan","volume":"24","author":"Malagola","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026042618471895900_oyag114-B8","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.3390\/jcm13092567","article-title":"Treatment-Free remission in chronic myeloid leukemia","volume":"13","author":"Bourne","year":"2024","journal-title":"J Clin Med"},{"key":"2026042618471895900_oyag114-B9","doi-asserted-by":"publisher","first-page":"17239","DOI":"10.1002\/cam4.6296","article-title":"Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia","volume":"12","author":"Chen","year":"2023","journal-title":"Cancer Med"},{"key":"2026042618471895900_oyag114-B10","doi-asserted-by":"publisher","first-page":"102421","DOI":"10.1016\/j.ejon.2023.102421","article-title":"Chronic myeloid leukaemia: a qualitative interview study exploring disease impact from patient and practitioner perspectives","volume":"67","author":"Hewison","year":"2023","journal-title":"Eur J Oncol Nurs"},{"key":"2026042618471895900_oyag114-B11","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2147\/PPA.S163393","article-title":"Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey","volume":"12","author":"Lou","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"2026042618471895900_oyag114-B12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/10428194.2020.1839655","article-title":"Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views","volume":"62","author":"Tromp","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2026042618471895900_oyag114-B13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/10428194.2017.1337114","article-title":"Patient perceptions of treatment-free remission in chronic myeloid leukemia","volume":"59","author":"Villemagne Sanchez","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2026042618471895900_oyag114-B14","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","article-title":"Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs","volume":"34","author":"Sharf","year":"2020","journal-title":"Leukemia"},{"key":"2026042618471895900_oyag114-B15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"key":"2026042618471895900_oyag114-B16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1748-5908-6-42","article-title":"The behaviour change wheel: a new method for characterising and designing behaviour change interventions","volume":"6","author":"Michie","year":"2011","journal-title":"Implement Sci"},{"key":"2026042618471895900_oyag114-B17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjhp.12705","article-title":"Attitudes and perceptions of cancer patients and healthcare providers towards prehabilitation: a thematic synthesis","volume":"29","author":"Shen","year":"2024","journal-title":"Br J Health Psychol"},{"key":"2026042618471895900_oyag114-B18","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1016\/j.sapharm.2021.12.004","article-title":"Key factors underlying the willingness of patients with cancer to participate in medication redispensing","volume":"18","author":"Smale","year":"2022","journal-title":"Res Social Adm Pharm"},{"key":"2026042618471895900_oyag114-B19","doi-asserted-by":"publisher","first-page":"e28216","DOI":"10.1002\/pbc.28216","article-title":"Applying the COM-B model to patient-reported barriers to medication adherence in pediatric acute lymphoblastic leukemia","volume":"67","author":"Heneghan","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2026042618471895900_oyag114-B20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12911-024-02806-7","article-title":"Development and alpha-testing of a patient decision aid for patients with chronic myeloid leukemia regarding dose reduction","volume":"24","author":"Lokhorst","year":"2024","journal-title":"BMC Med Inform Decis Mak"},{"key":"2026042618471895900_oyag114-B21","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1093\/pm\/pnw078","article-title":"Patients\u2019 perspectives on tapering of chronic opioid therapy: a qualitative study","volume":"17","author":"Frank","year":"2016","journal-title":"Pain Med"},{"key":"2026042618471895900_oyag114-B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/msc.1367","article-title":"Dose reduction of biologic therapy in inflammatory arthritis: a qualitative study of patients\u2019 perceptions and needs","volume":"17","author":"Hewlett","year":"2019","journal-title":"Musculoskeletal Care"},{"key":"2026042618471895900_oyag114-B23","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00403-023-02566-w","article-title":"Patients\u2019 perspectives towards biologic dose reduction in psoriasis: a qualitative study","volume":"315","author":"van der Schoot","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2026042618471895900_oyag114-B24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3324\/haematol.2025.287772","article-title":"Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey","volume":"111","author":"Lang","year":"2026","journal-title":"Haematologica"},{"key":"2026042618471895900_oyag114-B25","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.pec.2015.06.022","article-title":"Shared decision making: Concepts, evidence, and practice","volume":"98","author":"Stiggelbout","year":"2015","journal-title":"Patient Educ Couns"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag114\/67664623\/oyag114.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag114\/68103122\/oyag114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag114\/68103122\/oyag114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:47:23Z","timestamp":1777243643000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag114\/8561086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag114","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,30]]},"article-number":"oyag114"}}